Abstract
Real-time tracking of prodrug uptake, delivery and activation in vivo represents a major challenge for prodrug development. Herein, we demonstrate the use of novel glycosylated theranostics of the cancer pharmacophore Amonafide in highly-selective, enzymatic triggered release. We show that the use of endogenous enzymes for activated release of the therapeutic component can be observed, in real time, and monitored using one and two-photon bioimaging, offering unique insight into the prodrug pharmacokinetic profile. Furthermore, we demonstrate that the potent cytotoxicity of Amonafide is preserved using this targeted approach.
Original language | English |
---|---|
Article number | e202103858 |
Number of pages | 7 |
Journal | Chemistry - A European Journal |
Volume | 28 |
Issue number | 3 |
Early online date | 24 Nov 2021 |
DOIs | |
Publication status | Published - 13 Jan 2022 |
Keywords
- antitumor agents
- carbohydrates
- glycosidase
- imaging agents
- prodrugs
ASJC Scopus subject areas
- Catalysis
- Organic Chemistry